BMO Capital Markets Reiterates “Outperform” Rating for Merck & Company, Inc. (NYSE:MRK)

BMO Capital Markets reaffirmed their outperform rating on shares of Merck & Company, Inc. (NYSE:MRK) in a research note issued to investors on Monday, July 24th. They currently have a $73.00 price target on the stock, down from their prior price target of $74.00.

Other equities research analysts have also recently issued reports about the stock. Vetr cut shares of Merck & from a strong-buy rating to a buy rating and set a $69.99 target price for the company. in a research report on Wednesday, May 17th. Zacks Investment Research upgraded shares of Merck & from a hold rating to a buy rating and set a $72.00 target price for the company in a research report on Wednesday, May 10th. Credit Suisse Group set a $72.00 target price on shares of Merck & and gave the company a buy rating in a research report on Tuesday, June 6th. BidaskClub upgraded shares of Merck & from a sell rating to a hold rating in a research report on Thursday, June 22nd. Finally, Citigroup Inc. set a $65.00 price objective on shares of Merck & and gave the company a hold rating in a report on Wednesday, July 5th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Merck & currently has an average rating of Hold and an average price target of $69.80.

Shares of Merck & (NYSE:MRK) traded up 0.55% during trading on Monday, hitting $62.52. 2,713,502 shares of the stock traded hands. Merck & has a 12 month low of $58.29 and a 12 month high of $66.80. The firm’s 50-day moving average price is $63.46 and its 200-day moving average price is $63.80. The stock has a market cap of $170.51 billion, a PE ratio of 33.85 and a beta of 0.80.

Merck & (NYSE:MRK) last issued its earnings results on Friday, July 28th. The company reported $1.01 EPS for the quarter, beating the Zacks’ consensus estimate of $0.87 by $0.14. The business had revenue of $9.93 billion during the quarter, compared to analysts’ expectations of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The company’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.93 earnings per share. Analysts anticipate that Merck & will post $3.87 EPS for the current year.

TRADEMARK VIOLATION WARNING: “BMO Capital Markets Reiterates “Outperform” Rating for Merck & Company, Inc. (NYSE:MRK)” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://stocknewstimes.com/2017/08/11/merck-co-s-nysemrk-outperform-rating-reaffirmed-at-bmo-capital-markets-updated-updated.html.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 6th. Stockholders of record on Friday, September 15th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 3.02%. The ex-dividend date of this dividend is Thursday, September 14th. Merck &’s payout ratio is 76.11%.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Marietta Wealth Management LLC acquired a new position in Merck & during the fourth quarter valued at approximately $538,000. Texas Yale Capital Corp. raised its position in Merck & by 50.8% in the fourth quarter. Texas Yale Capital Corp. now owns 46,695 shares of the company’s stock valued at $2,749,000 after buying an additional 15,730 shares during the last quarter. Ativo Capital Management LLC acquired a new position in Merck & during the fourth quarter valued at approximately $1,542,000. MML Investors Services LLC acquired a new position in Merck & during the fourth quarter valued at approximately $284,000. Finally, Ally Financial Inc. acquired a new position in Merck & during the fourth quarter valued at approximately $1,177,000. 73.73% of the stock is owned by institutional investors and hedge funds.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & (NYSE:MRK)




Receive News & Ratings for Merck & Company Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Merck & Company Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

4 + 14 =